N
Nan Lin
Researcher at Harvard University
Publications - 1220
Citations - 65601
Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.
Papers
More filters
Journal ArticleDOI
Self-awareness in neurodegenerative disease relies on neural structures mediating reward-driven attention
TL;DR: Patients' tendency to under-represent their functional decline was related to degeneration of domain-general dorsal frontal regions involved in attention, as well as orbitofrontal and subcortical regions likely involved in assigning a reward value to self-related processing and maintaining accurate self-knowledge.
Journal ArticleDOI
Occupational Prestige in Urban China
TL;DR: In this article, the authors report ratings of occupational prestige by urban residents in Beijing, China using a representative sample (N = 1,632) of adults aged 20-64 and a selected group of 50 occupations.
Journal ArticleDOI
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models
Luke Whitesell,Sandro Santagata,Sandro Santagata,Marc L. Mendillo,Nan Lin,David A. Proia,Susan Lindquist,Susan Lindquist +7 more
TL;DR: Results in culture and in mice provide support for a readily implemented strategy by which the heterogeneity and evolvability of metastatic ER+ breast tumors, and perhaps other advanced cancers, might be controlled and provide promising proof of principle for a generalizable strategy to combat the pervasive problem of rapidly emerging resistance to molecularly targeted therapeutics.
Journal ArticleDOI
Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer.
TL;DR: Very small tumors with four positive LNs may predict for higher BCSM compared with larger tumors, and in extensive node-positive disease, very small tumor size may be a surrogate for biologically aggressive disease.
Journal ArticleDOI
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Jing Ni,Shakti Ramkissoon,Shakti Ramkissoon,Shaozhen Xie,Shom Goel,Daniel G. Stover,H Guo,Victor Luu,Eugenio Marco,Lori A. Ramkissoon,Yun Jee Kang,Marika Hayashi,Quang-Dé Nguyen,Azra H. Ligon,Rose Du,Elizabeth B. Claus,Elizabeth B. Claus,Brian M. Alexander,Brian M. Alexander,Guo-Cheng Yuan,Zhigang C. Wang,J. Dirk Iglehart,Ian E. Krop,Thomas M. Roberts,Eric P. Winer,Nan Lin,Keith L. Ligon,Keith L. Ligon,Jean J. Zhao +28 more
TL;DR: Findings suggest that a biomarker-driven clinical trial of PI3K inhibitor in combination with an mTOR inhibitor should be conducted for patients with HER2-positive BCBM.